GlassScriptPhysician profile
Samer Kebbeh
NPI 1922629112
$7,195.19
in general payments reported to CMS, 2019-2025
36 companies · $5,011 in 2025
The $5,011 reported for 2025 was more than what 99% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $62.62 · 2023: $228 · 2024: $1,893 · 2025: $5,011.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,025 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,024.58 |
| Education | $107.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $961.34 | 2023-2025 | |
| Biogen, INC. | $879.22 | 2024-2025 | Vumerity, Tysabri, Leqembi |
| Novartis Pharmaceuticals Corporation | $736.37 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $603.25 | 2024-2025 | Ultomiris |
| Emd Serono, INC. | $447.59 | 2024-2025 | Mavenclad |
| Pfizer INC. | $392.81 | 2024-2025 | |
| Lundbeck LLC | $348.41 | 2025 | Vyepti |
| Sk Life Science, INC. | $321.25 | 2024-2025 | |
| Argenx US, INC. | $293.02 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Amneal Pharmaceuticals LLC | $287.13 | 2024-2025 | Crexont |
| Ucb, INC. | $277.86 | 2024-2025 | Fintepla, Nayzilam, Zilbrysq |
| Amgen INC. | $246.08 | 2025 | Uplizna |
| Eisai INC. | $177.88 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $154.87 | 2025 | Rexulti |
| Genentech USA, INC. | $117.95 | 2024-2025 | Ocrevus Zunovo |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $115.54 | 2024-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Neurocrine Biosciences, INC. | $110.08 | 2025 | |
| Lilly USA, LLC | $81.55 | 2024-2025 | Kisunla, Amyvid, Emgality |
| Teva Pharmaceuticals USA, INC. | $74.29 | 2025 | Austedo Xr |
| Impel Pharmaceuticals INC. | $62.62 | 2022 | |
| Tonix Medicines, INC. | $58.14 | 2025 | Zembrace Symtouch, Tonmya |
| Forte Bio-Pharma LLC | $55.38 | 2025 | Tanlor |
| Mdd US Operations, LLC | $50.89 | 2025 | Gocovri |
| Merz Pharmaceuticals, LLC | $44.29 | 2024-2025 | Inbrija, Xeomin |
| Alnylam Pharmaceuticals INC. | $37.23 | 2024 | Amvuttra |
| Noven Therapeutics, LLC | $35.29 | 2025 | Xelstrym |
| Mallinckrodt Hospital Products INC. | $31.75 | 2025 | Acthar |
| Tg Therapeutics, INC. | $31.00 | 2025 | |
| Janssen Biotech, INC. | $29.18 | 2025 | |
| Octapharma USA, INC. | $23.63 | 2025 | Panzyga |
| Jazz Pharmaceuticals INC. | $22.77 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $21.10 | 2025 | Wainua |
| Axsome Therapeutics, INC. | $19.00 | 2025 | Symbravo |
| Scilex Pharmaceuticals INC. | $18.74 | 2025 | |
| Acadia Pharmaceuticals INC | $15.68 | 2025 | Nuplazid |
| Harmony Biosciences LLC | $12.01 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samer Kebbeh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.